Dr. Siegel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
36500 Aurora Dr
Summit, WI 53066Phone+1 262-434-1000
Summary
- Dr. Adam Siegel is an oncologist in Summit, WI and is affiliated with multiple hospitals in the area, including Aurora St. Luke's Medical Center, Aurora West Allis Medical Center, Aurora Sheboygan Memorial Medical Center, Aurora Medical Center Summit, and Aurora Medical Center. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 8 years. He specializes in hematologic oncology and is experienced in hematologic oncology, hematology, and oncology.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2012 - 2015- University of California (San Francisco)Residency, Internal Medicine, 2009 - 2012
University of Wisconsin School of Medicine & Public HealthClass of 2009
Certifications & Licensure
CA State Medical License 2010 - Present
WI State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 67 citationsAt What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical TrialsHala T. Borno, Li Zhang, Adam Siegel, Emily Chang, Charles J. Ryan
The Oncologist. 2018-10-01 - 8 citationsA bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recru...Celia P. Kaplan, Adam Siegel, Yan Leykin, Nynikka R. Palmer, Hala T. Borno
Contemporary Clinical Trials Communications. 2018-08-15 - 23 citationsA Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant P...Xiao X. Wei, Adam Siegel, Rahul Aggarwal, Amy M. Lin, Terence W. Friedlander
The Oncologist. 2018-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
